-
Trains collide near Jakarta, killing four, injuring dozens
-
Kompany hails Kane, 'ageing like fine wine' as Bayern face PSG in Champions League
-
UK's King Charles arrives in US to shore up Trump ties
-
Tuareg rebels in control of key Mali town
-
US Supreme Court hears Bayer bid to end Roundup weedkiller suits
-
Separate goals, common enemy for Mali's jihadists and separatists
-
Accused media gala shooter charged with attempted Trump assassination
-
UK's King Charles seeks to shore up Trump ties
-
Tourism plummets in US-blockaded Cuba
-
Taylor Swift files to trademark her voice amid AI clone boom
-
Trains collide outside Jakarta, killing four: officials
-
EU tells Google to open Android to AI rivals
-
Italian Calzona quits as Slovakia coach
-
21 killed in deadliest Colombia bombing in decades
-
Hazlewood, Kumar spark Delhi collapse as Bengaluru romp to victory
-
UN maritime agency rejects Hormuz tolls
-
Human Rights Watch warns of 'exclusion and fear' at World Cup
-
Tuareg rebels in control of key Mali town after offensive
-
Joshua signs deal to face Fury in all-British grudge match
-
Melania Trump slams Kimmel joke likening her to an 'expectant widow'
-
Carney launches $18 billion Canada sovereign wealth fund
-
Modric suffers fractured cheekbone, will go under the knife: AC Milan
-
'Looming' risk of nuclear arms race, UN proliferation meeting hears
-
Suspect due in court over shooting at Trump gala
-
Sabalenka downs Osaka to reach Madrid Open quarter-finals
-
'Nobody is better than us' says Luis Enrique as PSG prepare for Bayern
-
Hridoy, Shamim pull off record home chase for Bangladesh against NZ
-
Thrilling Kvaratskhelia hoping to drive PSG to another Champions League final
-
Swiss canton votes with centuries-old show of hands
-
Mali attacks kill defence minister, deepening security crisis
-
How remarkable Sawe made marathon history in London
-
British Open to be staged at Royal Lytham and St Annes in 2028
-
Mbappe doubt for Clasico after Real Madrid confirm thigh injury
-
Salah will get fitting Liverpool farewell despite injury, says Van Dijk
-
African players in Europe: Injury may end Salah's Liverpool reign
-
China blocks Meta's acquisition of AI firm Manus
-
US woman speaks of ordeal in France Al-Fayed trafficking probe
-
French teen faces jail in Singapore for licking vending machine straw
-
Iran FM blames US for failure of talks after landing in Russia
-
Steep mountainside offers respite for daring Afghans
-
Teenage wonder Sooryavanshi says criticism 'affects me a bit'
-
Japan startup seeks approval of cat kidney disease treatment
-
Technician dies installing stage for Shakira concert in Rio
-
Cut off from the West, Muscovites rediscover Russian 'roots'
-
'Joint venture in reverse': foreign carmakers seek edge with China partners
-
Nations backing fossil fuel exit 'a new power': conference host Colombia
-
Rockets thrash Lakers, Wembanyama triumphant on Spurs return
-
ECB set to hold rates steady with eye on Iran crisis
-
Team-first Kane propelling Bayern to glory as PSG showdown looms
-
Pogacar vows to keep going until Seixas 'destroys' him
Sartorius Sharpens Climate Targets and Receives Validation from Science Based Targets Initiative
Ambitious new medium-term targets set for Scopes 1, 2, and 3
SBTi confirms compatibility of science-based reduction targets with Paris Climate Agreement
Long-term ambition remains unchanged: net-zero greenhouse gas emissions by 2045
GÖTTINGEN, DE / ACCESS Newswire / February 16, 2026 / The life science group Sartorius has sharpened its medium-term climate targets and received validation from the Science Based Targets initiative (SBTi). The organization confirmed that the new greenhouse gas reduction targets are in line with the Paris Climate Agreement.
"We have refined our climate targets and, with SBTi validation, taken an important step that is increasingly expected in our industry: science-based targets aligned with the United Nations' decarbonization pathways. This underscores our level of ambition," said Sartorius CEO Dr. Michael Grosse. "At the same time, we are turning ambition into action: We are transitioning our sites to renewable energy, working closely with customers and suppliers to advance the use of low-emission materials and processes, and applying eco-design principles to a growing share of our product portfolio. This is how we reduce our own footprint and help our customers achieve their sustainability goals."
For direct emissions from its own operations and vehicle fleet, as well as indirect emissions from purchased energy - Scopes 1 and 2 -, Sartorius aims to reduce CO₂ equivalents in metric tons by 42 percent by 2030 compared with the base year 2022. The target now covers all relevant emission sources and exceeds the 95 percent coverage required by the Science Based Targets initiative. According to SBTi criteria, it is therefore aligned with the United Nations' 1.5-degree Celsius target. The most important lever for reducing Scope 1 and 2 emissions at Sartorius remains the global transition of sites to renewable energy. An increasing number of facilities are to source electricity from renewable sources and heat, cooling, and steam is also planned to be generated sustainably.
For indirect emissions along the company's value chain, the Sartorius Executive Board has defined an intensity target, assuming continued business growth: The company plans to reduce its Scope 3 emissions by 51.6 percent by 2030 compared to 2022 relative to the company's value added1. The most important drivers are the decarbonization of the supply chain together with customers and suppliers, the eco-design of products and packaging, logistics, and sustainable building construction.
The company's long-term climate ambition remains unchanged: Sartorius aims to have a climate-neutral value chain by 2045 and achieve net-zero greenhouse gas emissions by eliminating all avoidable emissions and offsetting the remaining ones.
The updated climate targets remain part of the long-term remuneration components of the Executive Board and replace the previous ones.
Learn more: http://www.sartorius.com/sustainability
A profile of Sartorius
Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.
Visit our newsroom and follow us on LinkedIn.
Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
[email protected]
SOURCE: SARTORIUS AG
View the original press release on ACCESS Newswire
G.Stevens--AMWN